Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Turkovac vs CoronaVac Booster in Adults
NCT04979949Phase 2Completed
- Sponsor
- TÜSEB
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of turkovac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by TÜSEB. Primary endpoints: Incidence of adverse reactions at 7 days and Incidence of Serious Adverse Events at 168 days. Started Jul 2021; status: completed.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04979949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979949.